Research progress of immune checkpoint LAG-3 in tumor immunity

doi:10.3877/cma.j.issn.2095-9141.2021.03.011

Abstract

Abstract:

Lymphocyte activating gene 3 (LAG-3) is an important inhibitory immune checkpoint in vivo that ensures immune homeostasis by inhibiting various lymphocyte activation and cytokine secretion. However, tumor cells often use this to undergo immune escape and LAG-3 have currently been found to be highly expressed in many types of tumor-infiltrating lymphocytes. In this paper, the gene, structure and function of LAG-3 and the role of dual blockade of LAG-3 and programmed deathreceptor-1 in cancer immunotherapy will be described in order to provide further reference for cancer immunotherapy.

Key words: Immune checkpoint, Lymphocyte activating gene 3, Programmed deathreceptor-1, Cancer immunotherapy

Jie Han, Jinhu Li, Xiaodong Liu, Wei Mu, Yimin Fan. Research progress of immune checkpoint LAG-3 in tumor immunity[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2021, 07(03): 182-186.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2021.03.011

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2021/V07/I03/182

Figures/Tables 1

References 41

[1]	Triebel F. LAG-3, a novel lymphocyte activation gene closely related to CD4[J]. J Exp Med, 1990, 171(5): 1393-1405.
[2]	Huard B, Mastrangeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein[J]. Proc Natl Acad Sci USA, 1997, 94(11): 5744-5749.
[3]	Crise B, Rose JK. Identification of palmitoylation sites on CD4, the human immunodeficiency virus receptor[J]. J Biol Chem, 1992, 267(19): 13593-13597.
[4]	Workman CJ, Dugger KJ, Vignali DA, et al. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3[J]. J Immunol, 2002, 169(10): 5392-5395.
[5]	Huard B, Mastrangeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein[J]. Proc Natl Acad Sci USA, 1997, 94(11): 5744-5749.
[6]	Kouo T, Huang L, Pucsek AB, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells[J]. Cancer Immunol Res, 2015, 3(4): 412-423.
[7]	Li N, Wang Y, Forbes K, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3[J]. EMBO J, 2007, 26(2): 494-504.
[8]	Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications[J]. J Immunother Cancer, 2020, 8(2): e001014.
[9]	Yayi H, Yan W, Sa Z, et al. sLAG-3 in non-small-cell lung cancer patients’serum[J]. Onco Targets Ther, 2018, 11: 4781-4784.
[10]	Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors[J]. Cancer Lett, 2006, 235(1): 147-153.
[11]	Li N, Jilisihan B, Wang W, et al. Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood[J]. Cancer Biomark, 2018, 23(3): 341-351.
[12]	Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT[J]. Curr Top Microbiol Immunol, 2017, 410: 127-156.
[13]	Hannier S, Tournier M, Bismuth G, et al. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling[J]. J Immunol, 1998, 161(8): 4058-4065.
[14]	Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells[J]. Eur J Immunol, 2003, 33(4): 970-979.
[15]	Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection[J]. Nat Immunol, 2009, 10(1): 29-37.
[16]	Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems[J]. J Clin Invest, 2007, 117(11): 3383-3392.
[17]	Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo[J]. PLoS One, 2014, 9(11): e109080.
[18]	Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells[J]. Immunity, 2004, 21(4): 503-513.
[19]	Liang B, Workman C, Lee J, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II[J]. J Immunol, 2008, 180(9): 5916-5926.
[20]	Bayry J, Triebel F, Kaveri SV, et al. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells[J]. J Immunol, 2007, 178(7): 4184-4193.
[21]	Casati C, Camisaschi C, Rini F, et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity[J]. Cancer Res, 2006, 66(8): 4450-4460.
[22]	Kisielow M, Kisielow J, Capoferri-Sollami G, et al. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells[J]. Eur J Immunol, 2010, 35(7): 2081-2088.
[23]	Workman CJ, Rice DS, Dugger KJ, et al. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)[J]. Eur J Immunol, 2015, 32(8): 2255-2263.
[24]	Lino AC, Dang VD, Vicky L, et al. LAG-3 Inhibitory receptor expression identifies immunosuppressive natural regulatory plasmacells[J]. Immunity, 2018, 499(1):120-133.e9.
[25]	Sun H, Sun C, Xiao W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations[J]. Cytokine, 2014, 65(1): 33-41.
[26]	Brignone C, Grygar C, Marcu M, et al. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells[J]. J Immunol, 2007, 179(6): 4202-4211.
[27]	Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma[J]. Clin Cancer Res, 2009, 15(19): 6225-6231.
[28]	Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-Infiltrating T cells in hepatocellular carcinomas[J]. Gastroenterology, 2017, 153(4): 1107-1119.e10.
[29]	Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems[J]. J Clin Invest, 2007, 117(11): 3383-3392.
[30]	Harris-Bookman S, Mathios D, Martin AM, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma[J]. Int J Cancer, 2018, 143(12): 3201-3208.
[31]	Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites[J]. J Immunol, 2010, 184(11): 6545-6551.
[32]	Sharma P, Allison J. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential[J]. Cell, 2015, 161(2): 205-214.
[33]	Fougeray S, Brignone C, Frédéric T. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321[J]. Vaccine, 2006, 24(26): 5426-5433.
[34]	Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma[J]. Clin Cancer Res, 2009, 15(19): 6225-6231.
[35]	Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action[J]. Nat Rev Immunol, 2015, 15(1): 45-56.
[36]	Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape[J]. Cancer Res, 2012, 72(4): 917-927.
[37]	Huang RY, Eppolito C, Lele S, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model[J]. Oncotarget, 2015, 6(29): 27359-27377.
[38]	Huang RY, Francois A, McGray AR, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer[J]. Oncoimmunology, 2016, 6(1): e1249561.
[39]	Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints[J]. Nat Commun, 2016, 7: 10501.
[40]	Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients[J]. J Exp Med, 2010, 207(10): 2175-2186.
[41]	Kraman M, Faroudi M, Allen NL, et al. FS118, a bispecific antibody targeting LAG-3 and PD-L1, enhances T-cell activation resulting in potent antitumor activity[J]. Clin Cancer Res, 2020, 26(13): 3333-3344.

Please choose a citation manager

Content to export